Biological Agent and Total Hip Arthroplasty in Rheumatoid Arthritis
The number of THAs performed for patients with RA may show an annual decrease resulting from early and aggressive drug therapy for management of RA in the era of BIO and JAKi. However, patients with RA undergoing THA have several unmet needs, including secondary osteoarthritis, dislocation, periprosthetic joint infection, and periprosthetic fracture with osteoporosis.
Authors
- Yuya Takakubo (ORCID: https://orcid.org/0000-0003-3535-8419)
- Michiaki Takagi (ORCID: https://orcid.org/0000-0002-3052-787X)
- Masaji Ishii (ORCID: https://orcid.org/0009-0005-7332-1897)
- Kan Sasaki (ORCID: https://orcid.org/0009-0000-8015-6379)
- Juji Ito (ORCID: https://orcid.org/0000-0002-3410-2940)
- Hiroharu Oki (ORCID: https://orcid.org/0009-0008-4983-239X)
Institutions
- Yamagata University (JP)
- Yamagata City Hospital Saiseikan (JP)
Publication Details
- Journal
- Hip & Pelvis
- Published
- 2024-12-01
- DOI
- https://doi.org/10.5371/hp.2024.36.4.273
- Citations
- 1
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.47